What's new

Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 8, Status: Authorised

Apr 23, 2025 - 15:35
 0
Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 8, Status: Authorised
Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 8, Status: Authorised
Read More

Tags:

Previous Article

Human medicines European public assessment report (EPAR): Pyzchiva, ustekinumab,...

Next Article

Anthropologie extends partnership with Kiss the Ground to promote regenerative a...

Related Posts

Changing the labelling and package leaflet (Article 61(3) notifications)

Changing the labelling and package leaflet (Article 61(...

Feb 18, 2025  0

Human medicines European public assessment report (EPAR): Rxulti, brexpiprazole, Date of authorisation: 26/07/2018, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 4, 2025  0

Human medicines European public assessment report (EPAR): Polivy, polatuzumab vedotin, Date of authorisation: 16/01/2020, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 21, 2025  0